Daming Shan

TL;DR: It is suggested that ligation of CD20 in vivo by anti-CD20 antibodies in the presence of FcR-expressing cells may initiate signal transduction events that induce elevation of [Ca2+]i and lead to apoptosis of malignant B cells, thereby contributing to the impressive tumor regressions observed in mouse models and clinical trials using anti- CD20 MoAbs.

TL;DR: Several of the signal-transduction events involved in the apoptosis of malignant B cells that transpire following ligation of CD20 by anti-CD20 antibodies in the presence of Fc-receptor-expressing cells or secondary goat anti-(mouse Ig) antibodies are identified and which may contribute to the tumor regressions observed in mouse models and clinical trials.

TL;DR: The CD22 B lymphocyte-surface Ag is internalized constitutively by unstimulated B cell lines and subsequently degraded in an acidic intracellular compartment (presumably lysosomes) without detectable recycling of the molecule back to the cell surface.

TL;DR: It is suggested that the GS1 scFv-Ig with a short linker peptide of approximately 5 aa is the best of the engineered constructs for future studies and demonstrated significantly superior binding to CD20-expressing target cells, compared with the other scFV-IG constructs.

TL;DR: In vitro effects of N-(4-hydroxyphenyl) retinamide (4-HPR) with and without anti-CD20 antibodies in B-cell lymphoma lines are evaluated to suggest that the potential in vivo synergy of these well-tolerated drugs may augment the previously demonstrated clinical activity of anti- CD20 monoclonal antibodies in the treatment of B- cell malignancies.